Skip to main content

Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

    MAINZ, GERMANY, October 1, 2021 (GLOBE NEWSWIRE) – BioNTech SE announced that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial. The trial has been initiated in the United States, Germany, Spain and Belgium. It is planned to enroll about 200 patients to evaluate the efficacy of RO7198457 (BNT122) compared to watchful waiting after surgery and chemotherapy, the current standard of care for these high-risk patients.

  • Gujarat State Pharmacy Council to offer financial assistance to family of pharmacist who died in Corona pandemic

    ​Gujarat State Pharmacy Council (GSPC) had organised celebration of World Pharmacist Day on 25th Sept 2021 in which more than 300 pharmacists from the pharmacy sector of the state of Gujarat were present. In this event GSPC announced financial assistance to the family of a Gujarat pharmacist who died while on duty in Corona pandemic.

  • DBT Institute to help Vietnamese company develop COVID vaccine

     After helping several Indian companies in the development of vaccines for COVID-19 including clinical trials, the Department of Biotechnology (DBT)’s Translational Health Science and Technology Institute (THSTI) has entered into a research collaboration with Nanogen Pharmaceutical Biotechnology JSC, a Vietnamese pharmaceutical company which is in the process of developing a vaccine for the disease.

  • Gut bacteria influence brain development

    Extremely premature infants are at a high risk for brain damage. Researchers at the University of Vienna and the Medical University of Vienna have now found possible targets for the early treatment of such damage outside the brain: Bacteria in the gut of premature infants may play a key role. The research team found that the overgrowth of the gastrointestinal tract with the bacterium Klebsiella is associated with an increased presence of certain immune cells and the development of neurological damage in premature babies.

  • COVID-19 has caused the biggest decrease in life expectancy since World War II

    The research team assembled an unprecedented dataset on mortality from 29 countries, spanning most of Europe, the US and Chile – countries for which official death registrations for 2020 had been published. They found that 27 of the 29 countries saw reductions in life expectancy in 2020, and at a scale which wiped out years of progress on mortality, according to the paper published today in the International Journal of Epidemiology.

  • AstraZeneca Pharma India Limited receives Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg Capsule

    AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule.

    Selumetinib can also cause cardiomyopathy, ocular toxicity including retinal vein occlusion, retinal pigment epithelial detachment and impaired vision, and increased creatinine phosphokinase. Selumetinib should be withheld, dosage reduced, or permanently discontinued based on the severity of adverse reactions.

  • Odisha Government allows pharmacists to dispense medicine in absence of doctors

    Due shortage of doctors in public healthcare facilities, the Odisha government has permitted pharmacists to treat minor ailments and dispense drugs for certain diseases in hospitals.

  • Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries

    Pfizer Inc and BioNTech SE announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies’ COVID-19 vaccine at a not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them. This expanded agreement brings the total number of doses to be supplied to the U.S. government for donation to these countries to one billion.

  • Lincoln Pharma acquires a plant in Gujarat to develop cephalosporin products

    Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies is planning to launch Cephalosporin products soon. Company has acquired a facility in Mehsana, Gujarat. Investment in Cephalosporin plant for Rs 30 crore including Croreicapacity expansion and modernisation of the facility. Acquisition and further capex will be funded from internal accruals. Company expects commercial operations from March 2022. The plant is expected to contribute sales of around Rs 150 crore in the next 3 years.

  • Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1%

    Glenmark Pharmaceuticals Ltd has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin®1 Foam, 1%, of Mylan Pharmaceuticals Inc.

    According to IQVIATM sales data for the 12 month period ending July 2021, the Evoclin® Foam, 1%, market2 achieved annual sales of approximately $12.0 million*.

Subscribe to Pharma News